EGFR and lung carcinoma: Moreover, as shown in Figures 2G,H, metformin dramatically increased the sensitivity of lung cancers to EGFR TKIs (G+M vs. G or O+M vs. O), especially of HCC827GR and HCC827OR cells, indicating that metformin overcame acquired resistance to EGFR TKIs.